返回 
加入收藏
药品集中采购制度的发展与改革研究
x
请在关注微信后，向客服人员索取文件
| 篇名： | 药品集中采购制度的发展与改革研究 |
| TITLE： | Research on the Development and Reform of Centralized Drug Procurement System |
| 摘要： | 目的：为我国药品集中采购模式的调整和改革提出政策建议。方法：回顾我国药品集中采购模式的发展过程，通过文献研究、走访调研、专家访谈发现问题，结合美国、新加坡的药品采购平台建设、药品集中采购组织（GPO）采购、医保支付控费管理经验，提出基于控费目标的我国招标采购基本模型假设及药品招标采购政策的改革建议。结果与结论：我国的药品招标采购制度经历了统购统销、分散采购为主、集中采购初创和调整、网上药品集中采购全面推行“、两标”（基本药物招标与非基本药物招标）合一与联合采购探索、国家药品招标采购试点等阶段。现阶段药品集中采购存在平台隶属关系多样“、两票制”政策下企业遴选可能涉嫌垄断、降价成为招标采购的最核心绩效指标、GPO采购探索涉嫌垄断经营等问题。本研究基于控费目标构建的模型分析结果显示，药品费用是效率、药品用量、价格的函数，价格高则费用高，效率低则费用高。未来药品招标采购的目标不应当单纯以控价为核心，而应当兼顾效率，使招标采购的作用回归到“以量换价”的本质功能。建议我国药品招标采购应建立采购方和支付方相对独立的统一平台，逐步规范集团化采购模式，发挥医保支付审核的控费功能来代替单纯降价，避免绝对性的统一最低价采购。 |
| ABSTRACT： | OBJECTIVE：To put forward policy suggestions for the adjustment and reform of centralized drug procurement mode in China. METHODS ：The evolution process of centralized drug procurement mode in China was reviewed ，and problems were found through literature research and expert interview. Combined with the experience of drug procurement platform construction，GPO procurement and medical insurance payment control fee management in the United States and Singapore ，the reform suggestions were put forward for basic model assumption of bidding procurement based on cost control target and drug bidding procurement policy. RESULTS & CONCLUSIONS ：China’s drug bidding procurement system has gone through the stages of unified purchase and marketing ，decentralized procurement ，centralized procurement start-up and adjustment ，comprehensive implementation of online centralized drug procurement ，exploration of the integration of “two bidding ”（bidding for essential medicine and bidding for non-essential medicine ）and joint procurement ，and pilot stage of national drug bidding and procurement. At the present stage ，there are many problems in centralized drug procurement ，such as the diversified subordination relationship of the platform ，the possible monopoly of enterprise selection under the policy of “two invoice system ”，price reduction becoming the core performance index of bidding procurement ，and the suspected monopoly operation of GPO procurement exploration. The model analysis based on the goal of cost control shows that drug cost is a function of efficiency ，drug quantity and price. High price leads to high cost ，while low efficiency leads to high cost. In the future ，the goal of drug bidding and procurement should not only foucs on price control ，but also on efficiency. The function of bidding and procurement will return to the essential function of “price for quantity ”. It is suggested that a relatively independent and unified platform should be established for drug bidding and procurement in China ，and the grouped procurement mode should be gradually standardized ，the expenditure control function of medical insurance payment audit should be exerted instead of simple price reduction ，and absolute unified lowest price procurement should be avoided. |
| 期刊： | 2020年第31卷第21期 |
| 作者： | 张雅娟，方来英 |
| AUTHORS： | ZHANG Yajuan ，FANG Laiying |
| 关键字： | 药品集中采购；招标采购；降价；垄断；集团采购组织；改革 |
| KEYWORDS： | Centralized drug procurement ；Bidding and |
| 阅读数： | 767 次 |
| 本月下载数： | 31 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
